Table 2. FLT3 status and relative... | American Society of Hematology

Table 2.

FLT3 status and relative percentage of mutant in PB or bone marrow from 44 AML patients at presentation and relapse

No.	Presentation				Relapse
No.	FLT3	% Mutant	Sample	% Blasts	FLT3	% Mutant	Sample	% Blasts
1	WT	—	PB MNC	90	WT	—	NA	76
2	WT	—	BM	97	WT	—	PB MNC	NA
3	WT	—	PB MNC	95	WT	—	BM	NA
4	WT	—	PB MNC	28	WT	—	BM	42
5	WT	—	NA	100	WT	—	BM	95
6	WT	—	NA	100	WT	—	BM	60
7	WT	—	PB	NA	WT	—	BM	85
8	WT	—	BM	98	WT	—	PB	52
9	WT	—	PB	95	WT	—	PB	80
10	WT	—	BM	89	WT	—	BM	96
11	WT	—	PB	99	WT	—	PB	99
12	WT	—	PB	80	WT	—	BM	NA
13	WT	—	BM	86	WT	—	BM	60
14	WT	—	BM	58	WT	—	BM	90
15	WT	—	BM	90	WT	—	BM	87
16^*	WT	—	BM	72	WT (ITD⁺)	(45)	BM (PB)	13 (87)
17	WT	—	BM	NA	WT	—	BM	11
18	WT	—	PB	78	WT	—	BM	56
19	WT	—	BM	90	WT	—	BM	64
20	WT	—	BM	90	WT	—	BM	74
21	WT	—	PB MNC	90	D835⁺	≈50	PB MNC	NA
22	WT	—	BM	87	D835⁺	≈50	BM	NA
23	WT	—	PB MNC	90	ITD⁺	42	BM	95
24	WT	—	BM	95	ITD⁺	38	BM	95
25	ITD⁺	20	PB MNC	53	WT	—	BM	55
26	ITD⁺	6	BM	88	WT	—	BM	92
27	ITD⁺	11	PB	80	WT	—	BM	82
28	ITD⁺	28	BM	94	WT	—	BM	85
29	ITD⁺	44	BM	95	WT	—	BM	44
30	D835⁺	≈50	BM	95	D835⁺	≈50	BM	96
31	D835⁺	≈50	BM	60	D835⁺	≈50	BM	60
32	ITD⁺	13	BM	55	ITD⁺	16	BM	96
33	ITD⁺	39	BM	51	ITD⁺	39	BM	60
34	ITD⁺	44	PB MNC	77	ITD⁺	45	NA	NA
35	ITD⁺	82	BM	97	ITD⁺	84	BM	92
36	ITD⁺	86	BM	86	ITD⁺	83	PB	93
37	ITD⁺	91	PB	70	ITD⁺	91	BM	NA
38	ITD⁺	5	BM	NA	ITD⁺	35	PB	97
39	ITD⁺	23	PB MNC	86	ITD⁺	88	BM	100
40	ITD⁺	25	PB	79	ITD⁺	50	PB	99
41	ITD⁺	26 + 2	BM	90	ITD⁺	56 + 14	BM	94
42	ITD⁺	28 + 3 + 1	BM	80	ITD⁺	41	BM	99
43	ITD⁺	40	PB MNC	88	ITD⁺	69	PB MNC	NA
44^†	ITD⁺	44	BM	89	ITD⁺	60	PB	NA

No.	Presentation				Relapse
No.	FLT3	% Mutant	Sample	% Blasts	FLT3	% Mutant	Sample	% Blasts
1	WT	—	PB MNC	90	WT	—	NA	76
2	WT	—	BM	97	WT	—	PB MNC	NA
3	WT	—	PB MNC	95	WT	—	BM	NA
4	WT	—	PB MNC	28	WT	—	BM	42
5	WT	—	NA	100	WT	—	BM	95
6	WT	—	NA	100	WT	—	BM	60
7	WT	—	PB	NA	WT	—	BM	85
8	WT	—	BM	98	WT	—	PB	52
9	WT	—	PB	95	WT	—	PB	80
10	WT	—	BM	89	WT	—	BM	96
11	WT	—	PB	99	WT	—	PB	99
12	WT	—	PB	80	WT	—	BM	NA
13	WT	—	BM	86	WT	—	BM	60
14	WT	—	BM	58	WT	—	BM	90
15	WT	—	BM	90	WT	—	BM	87
16^*	WT	—	BM	72	WT (ITD⁺)	(45)	BM (PB)	13 (87)
17	WT	—	BM	NA	WT	—	BM	11
18	WT	—	PB	78	WT	—	BM	56
19	WT	—	BM	90	WT	—	BM	64
20	WT	—	BM	90	WT	—	BM	74
21	WT	—	PB MNC	90	D835⁺	≈50	PB MNC	NA
22	WT	—	BM	87	D835⁺	≈50	BM	NA
23	WT	—	PB MNC	90	ITD⁺	42	BM	95
24	WT	—	BM	95	ITD⁺	38	BM	95
25	ITD⁺	20	PB MNC	53	WT	—	BM	55
26	ITD⁺	6	BM	88	WT	—	BM	92
27	ITD⁺	11	PB	80	WT	—	BM	82
28	ITD⁺	28	BM	94	WT	—	BM	85
29	ITD⁺	44	BM	95	WT	—	BM	44
30	D835⁺	≈50	BM	95	D835⁺	≈50	BM	96
31	D835⁺	≈50	BM	60	D835⁺	≈50	BM	60
32	ITD⁺	13	BM	55	ITD⁺	16	BM	96
33	ITD⁺	39	BM	51	ITD⁺	39	BM	60
34	ITD⁺	44	PB MNC	77	ITD⁺	45	NA	NA
35	ITD⁺	82	BM	97	ITD⁺	84	BM	92
36	ITD⁺	86	BM	86	ITD⁺	83	PB	93
37	ITD⁺	91	PB	70	ITD⁺	91	BM	NA
38	ITD⁺	5	BM	NA	ITD⁺	35	PB	97
39	ITD⁺	23	PB MNC	86	ITD⁺	88	BM	100
40	ITD⁺	25	PB	79	ITD⁺	50	PB	99
41	ITD⁺	26 + 2	BM	90	ITD⁺	56 + 14	BM	94
42	ITD⁺	28 + 3 + 1	BM	80	ITD⁺	41	BM	99
43	ITD⁺	40	PB MNC	88	ITD⁺	69	PB MNC	NA
44^†	ITD⁺	44	BM	89	ITD⁺	60	PB	NA

MNC indicates mononuclear cells; BM, bone marrow; PB, peripheral blood; NA, not available.

Information in parentheses relates to second relapse.

Different mutations were detected at presentation and relapse.